Melissa G Ooi
Overview
Explore the profile of Melissa G Ooi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gill H, Raghupathy R, Hou H, Cheng-Hong Tsai X, Tantiworawit A, Ooi M, et al.
Blood Adv
. 2024 Dec;
9(4):862-876.
PMID: 39693517
The Acute Promyelocytic Leukemia (APL) Asian Consortium analyzed a contemporaneous cohort of newly diagnosed patients with APL treated with and without frontline arsenic trioxide (ATO) in 6 centers. The objectives...
2.
Tso A, Chng W, Goh Y, Ooi M, Chen Y, Nagarajan C, et al.
Clin Hematol Int
. 2024 Oct;
6(4):53-66.
PMID: 39417013
Singapore leads Southeast Asia in the routine use of daratumumab for multiple myeloma and other plasma cell dyscrasias. This retrospective review analyzed 112 patients who received daratumumab between 2012 and...
3.
Bayani D, Lin Y, Nagarajan C, Ooi M, Tso A, Cairns J, et al.
Pharmacoecon Open
. 2024 Jun;
8(5):651-664.
PMID: 38900407
Background And Objective: This study aimed to assess the cost-effectiveness of two regimens regarded as the standard of care for the treatment of newly diagnosed, transplant-ineligible multiple myeloma in Singapore:...
4.
Bayani D, Lin Y, Ooi M, Tso A, Wee H
EJHaem
. 2023 Nov;
4(4):1013-1018.
PMID: 38024607
Multiple myeloma, a hematological malignancy, imposes a significant financial burden on healthcare systems. Health technology assessments (HTA) and economic evaluations play vital roles in reimbursement decisions and cost containment. This...
5.
Chan J, Zhang B, Chew X, Salhi A, Kwok Z, Lim C, et al.
Nat Cell Biol
. 2022 May;
24(6):928-939.
PMID: 35618746
Most mammalian genes generate messenger RNAs with variable untranslated regions (UTRs) that are important post-transcriptional regulators. In cancer, shortening at 3' UTR ends via alternative polyadenylation can activate oncogenes. However,...
6.
Yow K, Liu X, Chai C, Tung M, Yan B, Christopher D, et al.
Asian Pac J Cancer Prev
. 2020 Sep;
21(9):2805-2810.
PMID: 32986384
JAK2 (V617F) allelic burden is the main genetic driver behind and a potential differentiator between individual myeloproliferative neoplasm (MPN) subtypes. This study aimed to explore the relationship between JAK2 (V617F)...
7.
8.
Soekojo C, Wang G, Chen Y, Casan J, Wolyncewicz G, Lin A, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Jun;
19(8):e470-e477.
PMID: 31171473
Background: The Revised International Staging System (R-ISS) has been widely adopted to prognosticate multiple myeloma. As a result, the continued utility of conventional metaphase karyotyping has been called into question....
9.
Teoh P, An O, Chung T, Chooi J, Toh S, Fan S, et al.
Blood
. 2018 Aug;
132(12):1304-1317.
PMID: 30061158
DNA alterations have been extensively reported in multiple myeloma (MM); however, they cannot yet fully explain all the biological and molecular abnormalities in MM, which remains to this day an...
10.
OConnor R, Ooi M, Meiller J, Jakubikova J, Klippel S, Delmore J, et al.
Cancer Chemother Pharmacol
. 2013 Apr;
71(5):1357-68.
PMID: 23589314
Purpose: Bortezomib is an important agent in multiple myeloma treatment, but resistance in cell lines and patients has been described. The main mechanisms of resistance described in cancer fall into...